| * Aortic Stiffness Does Not Mediate the Relation Between Pulse Pressure and CRP |
| * Clinical Significance of Coronary Calcification |
| * Correction for Villablanca et al., Arterioscler Thromb Vasc Biol 24 (6) 1055-1061. |
| * Serum Lipid Levels and the Risk of Venous Thrombosis |
| * PI3K-Akt Pathway Suppresses Coagulation and Inflammation in Endotoxemic Mice |
| * C-Reactive Protein, Fibrin D-Dimer, and Risk of Ischemic Heart Disease |
| * Segment-Specific Effects of Cardiovascular Risk Factors on Carotid Artery Intima-Medial Thickness in Women at Midlife |
| * Low-Density Lipoprotein Particle Size Loci in Familial Combined Hyperlipidemia |
| * Quantitative Trait Loci for Apolipoprotein B, Cholesterol, and Triglycerides in Familial Combined Hyperlipidemia Pedigrees |
| * Hyplip2, a New Gene for Combined Hyperlipidemia and Increased Atherosclerosis |
| * Gene Expression Phenotypes of Atherosclerosis |
| * Hemodynamic Regulation of CD34+ Cell Localization and Differentiation in Experimental Aneurysms |
| * Inhibition of Cholesteryl Ester Transfer Protein Activity by JTT-705 Increases Apolipoprotein E–Containing High-Density Lipoprotein and Favo |
| * High-Density Lipoproteins Retard the Progression of Atherosclerosis and Favorably Remodel Lesions Without Suppressing Indices of Inflammatio |
| * Blockade of Keratinocyte-Derived Chemokine Inhibits Endothelial Recovery and Enhances Plaque Formation After Arterial Injury in ApoE-Deficie |
| * Antimonocyte Chemoattractant Protein-1 Gene Therapy Attenuates Graft Vasculopathy |
| * Mast Cells in Neovascularized Human Coronary Plaques Store and Secrete Basic Fibroblast Growth Factor, a Potent Angiogenic Mediator |
| * C-Reactive Protein Genotypes Affect Baseline, but not Exercise Training–Induced Changes, in C-Reactive Protein Levels |
| * Can Exercise Training With Weight Loss Lower Serum C-Reactive Protein Levels? |
| * C-Reactive Protein-Induced In Vitro Vasorelaxation Is an Artefact Caused by the Presence of Sodium Azide in Commercial Preparations |
| * Contrasting Effects of Oral Versus Transdermal Estrogen on Serum Amyloid A (SAA) and High-Density Lipoprotein–SAA in Postmenopausal Women |
| * Exogenous NADPH Increases Cerebral Blood Flow Through NADPH Oxidase–Dependent and –Independent Mechanisms |
| * Cortical Microvascular Remodeling in the Stenotic Kidney |
| * Carbon Monoxide Protects Against Cardiac Ischemia—Reperfusion Injury In Vivo via MAPK and Akt—eNOS Pathways |
| * Inhibition of Rho-Kinase Leads to Rapid Activation of Phosphatidylinositol 3-Kinase/Protein Kinase Akt and Cardiovascular Protection |
| * In Vivo Transcriptional Response of Cardiac Endothelium to Lipopolysaccharide |
| * REDD2 Gene Is Upregulated by Modified LDL or Hypoxia and Mediates Human Macrophage Cell Death |
| * Oxidized Low-Density Lipoproteins Stimulate Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) Release by Coronary Smooth Muscle Cells |
| * Endogenous Nitric Oxide Synthesis Inhibitor Asymmetric Dimethyl L-Arginine Accelerates Endothelial Cell Senescence |
| * ADP Receptor P2Y12 Is Expressed in Vascular Smooth Muscle Cells and Stimulates Contraction in Human Blood Vessels |
| * Expression of Angiopoietin-2 in Endothelial Cells Is Controlled by Positive and Negative Regulatory Promoter Elements |
| * PECAM-1 Interacts With Nitric Oxide Synthase in Human Endothelial Cells |
| * Proinflammatory Cytokines Regulate LOX-1 Expression in Vascular Smooth Muscle Cells |
| * Leukotriene B4 Strongly Increases Monocyte Chemoattractant Protein-1 in Human Monocytes |
| * Finding Vulnerable Atherosclerotic Plaques |
| * Endothelium-Targeted Gene and Cell-Based Therapies for Cardiovascular Disease |
| * Regulation of Plasma High-Density Lipoprotein Levels by the ABCA1 Transporter and the Emerging Role of High-Density Lipoprotein in the Treat |
| * Hepatic Lipase, Lipoprotein Metabolism, and Atherogenesis |
| * Vascular Cross-Talk: A Conversation |
| * Molecular Phenotypes of Atherosclerosis |
| * CRP and Risk of Coronary Heart Disease |
| * Estrogen and HDL |